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Results: Results: in the 4 groups the results in terms of D90 
are respectively 123±32Gy, 146±28Gy, 153±23Gy, 166±17Gy, 
as shown in Figure 1. The dose fall-off in terms of D90 is 
respectively 58Gy, 43Gy, 37Gy, 21Gy (as shown in Figure 2) 
and in terms of V100 17%, 10%, 8%, 4%. In the last group the 
mean theoretical D90 and V100 are 187Gy and 99%, against a 
real implant evaluation of 186Gy and 99%and the maximum 
urethra dose is 210Gy in the planning and 219Gy at the end of 
the implant. In the 30% of the patients of the “real-time” 
group we changed the number of seeds or needles 
composition during the implant, to reach the desired 
constraints and PTV coverage. 
 
 
Conclusion: Conclusion: our work shows the impact of the 
“image-guided” technology evolution on the dose fall-off 
both in terms of D90 and V100. Moreover, we show how the 
“real-time” method allows to change the “theoretical” plan 
during the implant, to reach the recommended constraints 
and PTV coverage [1]. 
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Purpose or Objective: We initially reported biochemical 
control rate of 97% at 4 years of followup (Brachytherapy, 
2009), which highlighted our methodology of limiting needle 
trauma, relying on Intra-operative, Real-Time computer 
assisted IO (Inverse Optimization) to reduce the number of 
sources and total activity without compromising dosimetric 
quality. This update was performed to confirm our earlier 
favorable BFFS outcomes. 
 
Material and Methods: Between 2001 and 2013, 491 patients 
underwent real-time IO-PSI. Only patients with a minimum of 
2 years of follow-up treated without supplemental IMRT were 
the subject of this analysis (N=315). Our dose objectives and 
constraints for real-time IO-PSI have previously been 
published and remain unchanged. The main dose objective 
intra-operatively was to achieve a V100 > 95% (Volume 
receiving > 95% of the prescribed dose). Patients were 
implanted with either 125I (PD=145 Gy) or 103Pd (PD =120 Gy). 
Toxicity was prospectively scored using the Radiation 
Oncology Group Toxicity scale and the International Prostate 
Symptom Score questionnaire. Biochemical control was 
determined using the nadir+2 ng/ml definition.  
 
Results: The mean and median followup was 58 and 54 
months respectively (range: 24-110 months). The NCCN risk 
classification for FR and IR patients were used. 125I sources 
were used for 93% of the implants, and 103Pd for 7%. 89% of 
patients presented with FR disease while 10% presented with 
IR, and in 2 cases HR. (1%). The median number of sources 
and total activity implanted were 65 and 999MBq, 
respectively. The median prostate volume implanted was 36 
cc. The median V100 was 95%. Absolute BNED was 97%. The 
10 year actuarial probability of biochemical control rate for 
all patients was 95%, with no difference observed between FR 
or IR patients (97% and 95% respectively) Late Gu and GI 
Grade 2 and higher toxicity was very low. With a minimum 
follow-up for 2 years, the late Grade 2 and Grade 3 GU 
toxicity was 19% and 1% respectively. The late Grade 2 and 3 
rectal bleeding rate was 1% and 0% respectively, with no 
Grade 4 toxicity observed.  
 
Conclusion: With extended follow-up of 10 years, real-time 
IO-PSI demonstrated excellent biochemical control rates with 
low incidence of toxicity confirming the validity of our 
original hypothesis and methodology of Inverse planning in 
real time for PSI, and comparing favorably to other 
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Purpose or Objective: Despite aggressive treatment with 
radiation therapy plus temozolomide (TMZ), the prognosis for 
glioblastoma remains poor. We investigated the potential of 
targeting signal transducer and activator of transcription-3 
(STAT3) to improve the therapeutic outcome of glioblastoma. 
 
Material and Methods: We evaluated the preclinical 
potential of a STAT3 inhibitor, Cpd188 combined with 
temozolomide and radiation in vitro assays using two 
established glioblastoma cell lines (U251, U87) and two 
patients-derived glioblastoma cell lines (GBL12, GBL28) and 
in vivo studies using nude mice bearing intracranial U251 
xenografts. 
 
Results: Cpd188 potentiated the radiosensitizing effect of 
TMZ in U251 cell which has high levels of p-STAT3 expression. 
Increased radiosensitizing effects of TMZ were associated 
with impaired DNA damage repair, apoptosis and the 
reversion of epithelial-mesenchymal transition (EMT). Cpd188 
delayed in vivo tumor growth both alone and in combination 
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with radiation and TMZ. We also confirmed the 
radiosensitizing effect of Cpd188 of GBL28 cell which was 
originated from a patient with high level of STAT3 expression 
and unmethylated MGMT. 
 
Conclusion: Targeting STAT3 using Cpd188 could be a viable 
therapeutic approach to improve the outcome of current 
standard therapy for glioblastoma patients having high p-
STAT3 expression regardless of MGMT methylation status. 
Work supported by the grant (#2013R1A1A2074531) from the 
Ministry of Science, ICT & Future Planning to In Ah Kim. 
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Purpose or Objective: Purpose: Stress responses in cancer 
cells are exaggerated over that of normal tissues include 
signal transduction pathways such as GRP78, PKC, PLC, Rho 
and others. Many of these regulators of cell viability 
translocate of the cell membrane during the stress response. 
Mechanisms of protein transport include motor and scaffold 
proteins such as Tax Interacting protein-1 (TIP-1), which 
translocates to the surface of the cell membrane of cancer 
cells following exposure to ionizing radiation. TIP1 is a 
scaffold protein that moves proteins to and from the cell 
membrane. It is over expressed in poor prognosis cancers.  
 
Material and Methods: Methods: We studied radiation 
induction of TIP1 by western immunoblot and flow 
cytometry. We used siRNA to knock down TIP1 in human GBM 
and NSCLC cell lines. We utilized Anti-TIP1 antibodies 
administered IV to mouse models of human cancer 
xenografts. We measured tumor growth delay. To assess the 
ability of mouse NK cells to target and kill anti-TIP1 antibody-
opsonized lung cancers, we cultured H460, or LLC cells in 96-
well plates at 37oC. After 40 hr., cells were irradiated with 3 
Gy (or shield) to induce TIP1 expression. Cells were 
continued in culture for 4 hr. 10 ug/ml 2C6F3, NMIgG, or 
media were added and incubated for an additional 2 hr. 
Murine NK cells were added and Incubated for 16 hr. 
Cytotoxicity was then determined by cancer cells cytolysis. 
anti-TIP1 antibodies (Ab) that bind to the PDZ domain of this 
protein were administered IV to mice bearing irradiated 
human cancers. 
 
Results: Results: Membrane protein western blots showed a 
significant increase in the expression of TIP-1 protein at 4 
and 24 hrs following irradiation with 3 Gy as compared to 0 
Gy untreated control tumors. Significant levels of the TIP-1 
membrane protein were also present in the irradiated 
tumors, but not in untreated controls, as demonstrated by 
immunohistochemistry. Near-infrared imaging studies showed 
significant targeting and binding of anti-TIP-1 Ab to 
irradiated tumors compared to untreated tumors and IgG 
controls at 72 hrs. Knockdown of TIP1 and blocking Abs that 
bind to the PDZ domain of TIP1 enhance cytotoxicity in 
cancer but not normal tissues. Anti-PDZ-domain Abs 
significantly enhanced cytotoxicity in D54, H1299, H460 and 
A549 human cancer cells. We studied the mechanisms by 
which the Abs enhance cytotoxity and improve tumor control. 
Abs activate caspases 2, 3/7 in irradiated cancers. Moreover, 
Anti-TIP1 antibodies bound to the surface of cancer cells 
activated immune effector cells. In mouse models of human 
cancers, Anti- TIP1 Abs enhanced tumor growth delay after 
radiotherapy when administered IV to mouse models of 
human cancer. 
 
Conclusion: Conclusion: Anti- TIP1 antibodies activate 
immune effector cells and enhance the efficacy of 
radiotherapy specifically in cancer without enhancing the 
response in normal tissues. TIP1 is a molecular target for the 
development of novel radiation sensitizing agents. 
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Purpose or Objective: YB-1, a protein increasingly 
associated with tumour progression and treatment resistance 
in prostate cancer, is the only known ligand of the Notch-3 
receptor. The Notch pathway is an evolutionarily conserved 
signaling system whose inhibition is under scrutiny as a novel 
therapeutic approach. We have previously identified elevated 
Notch-3 mRNA expression in high grade prostate cancer. This 
study investigated the anti-tumour properties of the YB-1 
inhibitor Fisetin, a dietary flavonoid, in an isogenic model of 
radioresistant prostate cancer cells in vitro.  
 
Material and Methods: An isogenic model of radioresistance 
was generated in 22Rv1 prostate cancer cells through 
exposure to 30 x 2-Gy dose fractions. YB-1 and Notch-3 
expression were determined by western blotting in parent, 
aged-matched and radioresistant cells following irradiation 
(5Gy) and/or 60uM Fisetin treatment (24hrs). Patterns of 
expression were related to modification in cell cycle 
distribution through analysis of PI staining by flow cytometry 
and clonogenic survival. The anti-tumour effects of fisetin 
were compared to those of two notch inhibitors DAPT and 
Batimastat.  
 
Results: Following a cumulative total dose of 60Gy, the 
resulting subline RR22Rv1 was associated with a significant 
increase in clonogenic survival (1.3 fold increase in survival 
after 2Gy and 2.2 fold increase after 10Gy) when compared 
to both parent 22Rv1 and aged-matched controls. YB-1 was 
detected in the cytoplasm of all three lines. Expression levels 
were elevated following irradiation (4Gy) in RR22Rv1. 
Radiation (5Gy) inhibited activation and nuclear translocation 
of Notch-3. Fisetin treatment led to a loss of Notch-3 
cytoplasmic expression in RR22Rv1 cells. DAPT and 
Batimastat did not affect clonogenic survival of 22RV1 and 
RR22Rv1 cells. Fisetin induced G2 cell cycle arrest and 
significantly reduced clonogenic survival in untreated and 5-
Gy irradiated parent and RR22Rv1 cells.  
 
Conclusion: This study identifies potential role of the YB-1-
Notch-3 interaction in the radioresistance of prostate cancer 
cells, and highlights fisetin as a novel therapeutic agent for 
the management of prostate cancer.  
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Purpose or Objective: More than 50% all cancer patients 
receive radiation therapy. Despite recent innovations, 
clinical delivery of curative radiation doses is strictly 
restricted by the proximal healthy tissues. Chemical/ 
biological agents to augment the radiosensitization of cancer 
cells are limited by severe off-target toxicity concerns. We 
propose a dual-targeting strategy using tumor vascular-
targeted gold nanoparticles (which amplify 
radiosensitization) combined with the conformal image-
guided radiation therapy to induce tumor vascular disruption. 
This is a unique concept with a clear translational path. 
